 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression...

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Raymond James initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO  Free Report) in a research note issued to investors on Thursday, StockNewsAPI reports. The firm issued an...

Raymond James Begins Coverage on BridgeBio Pharma (NASDAQ:BBIO)

Investment analysts at Raymond James started coverage on shares of BridgeBio Pharma (NASDAQ:BBIO  Get Free Report) in a research report issued on Thursday, StockNewsAPI reports. The brokerage...

BridgeBio Pharma (NASDAQ:BBIO) Earns Outperform Rating from Analysts at Raymond James

This is a Bullish indicator signaling BBIO's price could rise from here. Traders may explore going long the stock or buying call options...

BridgeBio Pharma (BBIO, $29.58) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ( BridgeBio or the Company ), a commercial-stage biopharmaceutical company focused on genetic diseases...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO  Get Free Report) have received an average rating of Moderate Buy from the twelve brokerages that are covering the company...

Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Price Target at $43.62

This is a signal that BBIO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

BridgeBio Pharma (BBIO, $28.17) RSI Indicator left the oversold zone on March 13, 2024

In trading on Friday, shares of BridgeBio Pharma Inc (BBIO) crossed below their 200 day moving average of 28.76, changing hands as low as 28.71 per share. BridgeBio Pharma Inc shares are...

Notable Two Hundred Day Moving Average Cross - BBIO

BridgeBio Pharma (NASDAQ:BBIO  Get Free Report) had its target price dropped by stock analysts at Mizuho from $60.00 to $53.00 in a note issued to investors on Tuesday, Benzinga reports. The...

BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $53.00

Investors in BridgeBio Pharma Inc (BBIO) saw new options become available today, for the April 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BBIO...

Interesting BBIO Put And Call Options For April 26th

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Volume (M)	343,710.00
52-Wk High	$44.32
52-Wk Low	$12.75

BBIO BridgeBio Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals